Did the FDA Approve BPC-157? What the July 2026 Advisory-Committee Vote Actually Did

No, the FDA did not approve BPC-157. What happened on July 23, 2026 is that the FDA’s Pharmacy Compounding Advisory Committee — an outside panel that advises the agency, abbreviated PCAC — voted 8–6, with one abstention, to recommend that BPC-157 be added to something called the 503A bulks list. That list names the ingredients a state-licensed pharmacy is allowed to use when it compounds a medication for an individual patient.

Two things follow from that, and both matter. First, a committee recommendation is advice: the panel cannot change the list, and FDA is free to disagree. Before anything actually changes, the agency has to go through formal rulemaking — publishing a proposed rule, taking public comment, then issuing a final rule. Second, and more fundamentally, compounding eligibility is not drug approval. FDA approval means the agency reviewed evidence and concluded a specific finished product is safe and effective for a specific use. That never happened here, and it was not what the committee was asked. BPC-157 is still an unapproved drug today, exactly as it was the morning before the meeting.

It helps to see the whole ladder, because almost every confusing headline comes from collapsing two rungs into one. A substance gets nominated for the 503A bulks list. FDA reviews it and may put it in front of the advisory committee. The committee hears the evidence and votes a recommendation, which is where we are now — and that recommendation is non-binding. FDA then decides whether to act, and if it does, it must run formal rulemaking: a proposed rule, a public comment period, and a final rule. Only at the end of that does a substance actually appear on the list.

Not one rung of that ladder is FDA approval. Approval is a separate pathway entirely, in which a sponsor submits clinical evidence for a specific finished product and FDA determines it is safe and effective for a specific use. Only a handful of peptide drugs have ever cleared it — semaglutide, tirzepatide, tesamorelin, bremelanotide and a few others. You can see the full list on which peptides are FDA-approved. Being eligible for a pharmacy to compound and being an approved drug are different things, and a substance can be one without ever being the other.

First, nothing was approved or cleared. The committee recommended; it did not decide. FDA has not acted, the bulks list is unchanged, and all seven substances remain unapproved drugs. Headlines using the word “cleared” are describing a vote that, by itself, changed no one’s legal position.

Second, this was not the lifting of a ban. These peptides did sit in 503A Category 2— FDA’s designation for substances that present significant safety risk and should not be compounded. But they came off that list in April 2026, months before this meeting, when their nominations were withdrawn. Crucially, coming off Category 2 did not move them to Category 1; it left them unlisted and under review. The July vote was the next, separate step — a recommendation to add them to the positive bulks list. Coming off a restriction list in April and being recommended for a permission list in July are two different actions, and merging them into a single “ban lifted” story misstates both. The full sequence, with dates, is laid out on our FDA peptide compounding status page.

This is the part most coverage skipped. The agency’s career review scientists did not support easing restrictions on any of the four peptides heard on day one, and the committee voted for them anyway. Their objection was more basic than efficacy. FDA staff told the panel there is no universally accepted chemical formula for several of these compounds — that it is genuinely unclear what, chemically, is in the vial. As FDA’s Russell Wesdyk put it during the meeting: “We’ve never faced a problem of, ‘What is it?’”

Mary Thanh Hai, who directs FDA’s Office of New Drugs, made a related point about how little of the grey-market supply chain is subject to any reporting requirement. And at least one committee member observed during the proceedings that the panel was discussing dosing, safety and efficacy when that was not what it had been asked to evaluate. None of this makes the vote illegitimate — advisory committees exist precisely so outside experts can reach a different judgment than staff. But it is a real signal about the state of the evidence, and it is worth knowing before you read a headline that says these compounds were “cleared.”

Honestly: nothing today. If a clinic or an online seller tells you the FDA just approved BPC-157, or that these peptides are newly legal and you should act before the window closes, that is a sales pitch resting on a misreading of a procedural vote. The rules governing what a pharmacy may compound are the same this week as last week, and they will stay that way until FDA finishes rulemaking. Anything sold to you in the meantime as “research use only” is not a prescription, is not dispensed by a licensed pharmacy, and carries no guarantee about what is actually in it — which, given what FDA’s own chemists said about identity, is not an abstract concern.

What has changed is that this is now a live regulatory question worth following. We track it. If you want to understand where a specific peptide stands, start with the regulatory tracker or the BPC-157 overview; if you want to know what is legal in this state, see is peptide therapy legal in Nevada.